S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NASDAQ:ATXS

Catabasis Pharmaceuticals Stock Forecast, Price & News

$4.83
-0.06 (-1.23%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.70
$4.99
50-Day Range
$4.35
$7.43
52-Week Range
$4.30
$47.82
Volume
15,373 shs
Average Volume
39,205 shs
Market Capitalization
$62.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.42
30 days | 90 days | 365 days | Advanced Chart
Receive ATXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Catabasis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Catabasis Pharmaceuticals logo

About Catabasis Pharmaceuticals

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Headlines

Astria Therapeutics Inc
October 22, 2021 |  reuters.com
Catabasis Pharmaceuticals, Inc. (ATXS)
September 11, 2021 |  ca.finance.yahoo.com
Catabasis Pharmaceuticals rebrands with new disease focus
September 8, 2021 |  bizjournals.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXS
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$12.15 per share

Profitability

Net Income
$-37.30 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,658,000
Market Cap
$62.83 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/21/2022
Next Earnings (Estimated)
3/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

96th out of 1,418 stocks

Pharmaceutical Preparations Industry

38th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Catabasis Pharmaceuticals (NASDAQ:ATXS) Frequently Asked Questions

Is Catabasis Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Catabasis Pharmaceuticals stock.
View analyst ratings for Catabasis Pharmaceuticals
or view top-rated stocks.

How has Catabasis Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Catabasis Pharmaceuticals' stock was trading at $26.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATXS shares have decreased by 81.9% and is now trading at $4.83.
View which stocks have been most impacted by COVID-19
.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Catabasis Pharmaceuticals
.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:ATXS) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.31. During the same period in the previous year, the company earned ($3.36) earnings per share.
View Catabasis Pharmaceuticals' earnings history
.

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals's stock reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for ATXS?

5 brokerages have issued 1 year target prices for Catabasis Pharmaceuticals' stock. Their forecasts range from $13.00 to $36.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Catabasis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the following people:
  • Jill C. Milne, President, Chief Executive Officer & Director
  • Noah Clauser, Chief Financial Officer
  • Maria C. Mancini, Vice President-Clinical Operations
  • Andrew Nichols, Chief Scientific Officer
  • Andrew A. Komjathy, Chief Commercial Officer

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ATXS."

How do I buy shares of Catabasis Pharmaceuticals?

Shares of ATXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catabasis Pharmaceuticals' stock price today?

One share of ATXS stock can currently be purchased for approximately $4.83.

How much money does Catabasis Pharmaceuticals make?

Catabasis Pharmaceuticals has a market capitalization of $62.83 million. The biotechnology company earns $-37.30 million in net income (profit) each year or ($54.2394) on an earnings per share basis.

How many employees does Catabasis Pharmaceuticals have?

Catabasis Pharmaceuticals employs 20 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

Where are Catabasis Pharmaceuticals' headquarters?

Catabasis Pharmaceuticals is headquartered at 100 High StreetFloor 28, Boston MA, 02110.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at (617) 349-1971, via email at [email protected], or via fax at 617-273-2637.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.